ArticleFrontiers in bioengineering and biotechnology2026
Securing the U.S. nucleic acid synthesis industry: a case for safe-harbor information sharing.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Compounding asymmetries in nucleic acid synthesis screening: policy pathways for strengthening global biosecurity governance.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The U.S. has issued guidelines for synthetic nucleic acid providers to screen order sequences and customers. However, these guidelines do not provide clear, enforceable requirements for the industry and place significant responsibility on providers to appropriately interpret and apply these guidelines. This, in turn, can lead to uneven implementation, inconsistent risk assessments, and exploitable vulnerabilities. We propose that a safe harbor information sharing network could function as a biosecurity force multiplier. Such a system would enable cross-provider analysis of order sequences and customer metadata, improve detection of suspicious activity, generate empirical evidence to refine definitions of sequences of concern and screening priorities, and provide a more robust foundation for the iterative improvement of policies, guidelines, and regulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.